编号：2022002 证券代码：000788 证券简称：北大医药 北大医药股份有限公司 2022 年 7 月 19 日 投资者关系活动记录表 | --- | --- | |----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ▇特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | 类别 | □现场参观 □电话会议 | | 参与单位名称 | □其他：（请文字说明其他活动内容） 未来生命谷科技有限公司：牛洪森、郑昶泽、张傲雪、施振业； 渝农商理财有限责任公司：刘小莉； | | 及人员姓名 ...

Financial Performance - Total revenue for Q3 2022 was ¥555,998,229.24, a decrease of 5.78% compared to the same period last year[5] - Net profit attributable to shareholders was ¥15,941,378.28, down 29.44% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥14,411,779.72, a decline of 36.36% compared to the previous year[5] - The total revenue for the third quarter of 2022 was CNY 1,556,984,364.28, a decrease of 8.06% compared to CNY 1,693,912,427.73 in the same period last year[34] - The net profit for the third quarter of 2022 was CNY 45,770,236.78, a decline of 17.54% from CNY 55,518,176.84 in the same quarter of the previous year[35] - The total comprehensive income for the third quarter was CNY 45,770,236.78, a decrease from CNY 55,518,176.84 in the same period last year[36] - Basic and diluted earnings per share were both CNY 0.0768, down from CNY 0.0931 year-over-year[36] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was ¥47,315,539.92, an increase of 92.34% year-on-year[8] - Cash inflow from operating activities totaled CNY 1,741,366,572.33, compared to CNY 1,805,515,693.93 in the previous year, reflecting a decline of approximately 3.55%[38] - The net cash flow from operating activities was CNY 47,315,539.92, an increase from CNY 24,600,318.25 in the same period last year[38] - Cash and cash equivalents as of September 30, 2022, were CNY 435,238,820.88, down from CNY 446,260,598.94 at the beginning of the year, representing a decrease of 2.29%[31] - Cash and cash equivalents at the end of the period were CNY 347,759,764.89, down from CNY 354,663,817.40 year-over-year[38] - The company reported a cash outflow of CNY 43,251,358.64 from financing activities, compared to -CNY 25,572,955.19 in the same period last year[38] - The company received CNY 110,858,307.68 in other operating cash, significantly higher than CNY 46,682,576.63 in the previous year[37] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,528,981,527.31, a decrease of 0.48% from the end of the previous year[5] - The total assets as of September 30, 2022, were CNY 2,528,981,527.31, slightly down from CNY 2,541,299,544.68 at the beginning of the year, a decrease of 0.48%[33] - The total liabilities decreased to CNY 1,162,297,366.50 from CNY 1,206,677,909.88, reflecting a reduction of 3.68%[33] Research and Development - Research and development expenses decreased by 68.19% to ¥6,257,913.86 for the first nine months of 2022[8] - The company's R&D expenses for the third quarter of 2022 were CNY 6,257,913.86, significantly lower than CNY 19,671,088.05 in the same period last year, a decrease of 68.17%[35] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 65,402[10] - The largest shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., holds 27.00% of the shares, totaling 160,896,260 shares[10] - The company’s major shareholders include Southwest Synthetic Pharmaceutical Group Co., Ltd., holding 160,896,260 shares, and Peking University Medical Industry Group Co., Ltd., holding 70,328,949 shares[11] Regulatory Approvals and Corporate Actions - The company received approval from the National Medical Products Administration for the chemical drug "Trimebutine Hydrochloride Sustained-Release Tablets" on January 11, 2022[12] - The company received approval from the National Medical Products Administration for the chemical drug "Compound Sulfamethoxazole Tablets," which passed the consistency evaluation of quality and efficacy for generic drugs[18] - The company obtained the drug registration certificate for "Olanzapine Tablets" from the National Medical Products Administration on July 21, 2022[25] - The company signed a supplementary agreement for a counter-guarantee contract with the related guarantor, achieving substantial progress in mitigating related guarantee risks[14] - The company reported that as of March 31, 2022, it had fully withdrawn RMB 243 million in deposits and interest from the financial company of the parent group, resolving related deposit risk issues[17] Market Activities - The company participated in the seventh batch of national centralized drug procurement on July 12, 2022, with plans to bid for "Cefminox Sodium Injection" and "Meropenem Injection," which passed the consistency evaluation[25] - The company disclosed a report on acquisitions on February 23, 2022, detailing its strategic moves in the market[15] - China International Capital Corporation was appointed as the financial advisor for the acquisition of the company by Beijing Medical Management Co., Ltd., with a continuous supervision period lasting 12 months from February 23, 2022[28] Stock Trading and Shareholder Changes - The company’s stock experienced abnormal trading fluctuations, with cumulative price deviations exceeding 20% on multiple occasions in March 2022[16] - On May 12, 2022, the shareholder Synthetic Group reduced its holdings by 3,500,000 shares, accounting for 0.5873% of the total share capital, leaving it with 166,856,260 shares, or 27.9966% of the total[19] - On May 17, 2022, the Synthetic Group further reduced its holdings by 2,461,400 shares, representing 0.4130% of the total share capital, bringing its total holdings down to 164,394,860 shares, or 27.5836%[20] - As of May 18, 2022, the Synthetic Group's cumulative reduction reached 2,980,000 shares, accounting for 0.5% of the total share capital, indicating that more than half of the planned reduction had been executed[21] - The Synthetic Group underwent a change in shareholder structure, now being a wholly-owned subsidiary of Fangzheng Commercial Management Co., Ltd., as of August 26, 2022[26] - The company received a notice on August 31, 2022, regarding the Synthetic Group's plan to further reduce its holdings[27]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,000,986,135.04, a decrease of 9.32% compared to ¥1,103,819,449.92 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was ¥29,831,478.53, down 9.38% from ¥32,919,319.32 in the previous year[23]. - The basic earnings per share for the reporting period was ¥0.0501, down 9.24% from ¥0.0552 in the same period last year[23]. - The diluted earnings per share also stood at ¥0.0501, reflecting the same percentage decrease of 9.24% compared to the previous year[23]. - The weighted average return on equity was 2.20%, a decline of 0.31% from 2.51% in the previous year[23]. - The company reported non-recurring losses totaling ¥570,205.36, primarily due to government subsidies and other operating income and expenses[27]. - The company achieved operating revenue of CNY 1,000.99 million in the first half of 2022, a decrease of 9.32% compared to the same period last year[39]. - The net profit attributable to the parent company was CNY 29.83 million, down 9.38% year-on-year[39]. - The total profit for the first half of 2022 was CNY 36,917,133.62, a decrease of 17.4% compared to CNY 44,596,340.06 in the same period of 2021[164]. - The company's sales expenses were CNY 271,409,025.58, a decrease of 24.7% compared to CNY 360,251,281.35 in the same period of 2021[164]. Cash Flow and Assets - The net cash flow from operating activities improved significantly to ¥19,915,683.15, a 165.56% increase from a negative cash flow of ¥30,376,374.32 in the same period last year[23]. - Cash and cash equivalents at the end of the reporting period were ¥434,018,368.92, a decrease of 2.79% from ¥446,260,598.94 at the end of the previous year[54]. - Accounts receivable increased to ¥1,237,108,023.86, representing 49.88% of total assets, up 2.04% from the previous year[54]. - Inventory increased to ¥147,478,025.86, accounting for 5.95% of total assets, up 1.01% from the previous year[54]. - The company reported a significant decrease in other business income, which fell by 39.70% to ¥1,288,126.39 from ¥2,136,293.37 in the previous year[50]. - Total assets at the end of the reporting period were ¥2,480,359,172.76, a decrease of 2.40% from ¥2,541,299,544.68 at the end of the previous year[23]. Research and Development - The company focuses on the research and development of innovative drugs and high-end generic drugs, with a product structure that includes anti-infective, analgesic, and psychiatric medications[35]. - The company reported a 24.66% decrease in sales expenses, amounting to CNY 271.41 million, compared to CNY 360.25 million in the previous year[49]. - R&D investment decreased by 21.89% to CNY 10.85 million from CNY 13.89 million in the previous year[49]. - The company focused on three main product areas: anti-infection, mental health, and pain relief, accelerating product R&D and approval processes[40]. - A new anti-infection product, Compound Sulfamethoxazole Tablets, successfully passed the consistency evaluation for generic drug quality and efficacy in the first half of 2022[40]. Market and Industry Trends - The pharmaceutical industry in China has maintained a good development trend, driven by increasing drug quality requirements and policies such as "consistent evaluation" and "volume-based procurement" that promote high-quality development[32]. - The company has established a nationwide marketing network and efficient pharmaceutical distribution system, covering drug sales, hospital procurement, and supply chain management[34]. - The main products include injectable antibiotics and analgesics, with specific applications for various infections and pain management[37]. - The OTC market development has expanded, with the product Celecoxib Capsules achieving significant breakthroughs since its launch on the OTC platform[41]. Corporate Governance and Compliance - The company has established long-term commitments to maintain its independence in operations, assets, finance, and governance from its controlling entity, Peking University Medical[85]. - The company has committed to reducing and regulating related party transactions, ensuring they are conducted at market prices and in compliance with legal requirements[86]. - The company emphasizes the importance of maintaining a sound corporate governance structure to safeguard its operational independence[85]. - The company strictly adheres to laws and regulations, ensuring timely and accurate information disclosure to protect shareholders' rights[79]. - There were no significant environmental violations or penalties reported during the period, indicating compliance with environmental standards[78]. Risks and Challenges - The company faces risks from industry policy changes, including drug approval and pricing pressures, and plans to enhance product quality and accelerate new product development[65]. - Rising raw material costs and drug price reductions pose significant risks, prompting the company to focus on new product launches and market promotion[66]. - Operational risks related to product quality and safety are being addressed by strict adherence to operational standards and comprehensive management systems[68]. - Management risks are acknowledged, with a commitment to strategic updates and improved internal controls to enhance operational capabilities[69]. Legal Matters - The company is actively involved in ongoing legal disputes that may impact its financial position and operational strategies[94]. - The total amount involved in the arbitration case with Hubei Zhengkong Pharmaceutical Co., Ltd. is ¥51.41 million, and it is expected to form a liability[94]. - The company has ongoing litigation with Chongqing Hesheng Pharmaceutical Co., Ltd. regarding asset transfer agreements, with the case currently under appeal[94]. - The company reported a total of ¥1.15 million in litigation costs related to various cases[94]. Shareholder Information - The company’s major shareholder, Composite Group, reduced its holdings by 3,500,000 shares, accounting for 0.5873% of the total share capital on May 12, 2022[130]. - Composite Group further reduced its holdings by 2,461,400 shares, representing 0.4130% of the total share capital on May 17, 2022, bringing the total reduction to 1%[131]. - The total number of ordinary shareholders at the end of the reporting period was 74,282[143]. - The company did not distribute cash dividends or issue new shares during the reporting period[74].

Financial Performance - The company's operating revenue for 2021 was ¥2,236,776,376.12, representing a 13.12% increase compared to ¥1,977,422,147.25 in 2020[19]. - The net profit attributable to shareholders for 2021 was ¥43,143,838.36, a 10.11% increase from ¥39,181,478.94 in 2020[19]. - The net cash flow from operating activities improved significantly to ¥59,142,996.49, compared to a negative cash flow of -¥68,141,309.55 in 2020, marking a 186.79% increase[19]. - The total assets at the end of 2021 were ¥2,541,299,544.68, a 10.19% increase from ¥2,306,200,821.07 at the end of 2020[19]. - The company reported a basic earnings per share of ¥0.0724 for 2021, up 10.20% from ¥0.0657 in 2020[19]. - The company achieved a revenue of 2.237 billion yuan, representing a year-on-year growth of 13.12%[39]. - The net profit attributable to the parent company was 43.14 million yuan, an increase of 10.11% compared to the previous year[39]. - Total revenue for 2021 reached ¥2,236,776,376.12, representing a year-on-year increase of 13.12% compared to ¥1,977,422,147.25 in 2020[56]. Dividend Distribution - The company plans to distribute a cash dividend of 0.23 RMB per 10 shares to all shareholders, based on a total of 595,987,425 shares[5]. - The company declared a cash dividend of 0.23 CNY per 10 shares, totaling 13,707,710.78 CNY, which represents 100% of the distributable profit[138]. - The total distributable profit for the period was 106,557,500.67 CNY, with a remaining undistributed profit of 92,849,789.89 CNY for future distribution[139]. - The company did not implement any stock dividend or capital reserve conversion into share capital during this profit distribution[139]. Business Operations and Strategy - The company has maintained its focus on the formulation business, drug distribution, and medical device distribution after divesting from raw material production and sales[18]. - The company is engaged in the research, production, and sales of chemical drug formulations, as well as medical circulation and services[29]. - The company focuses on the research and development of innovative drugs and high-end generic drugs in the fields of anti-infection, analgesics, and mental health[34]. - The company has implemented strategic adjustments to mitigate the impact of pharmaceutical policy changes and ensure stable future revenue[39]. - The company is actively exploring new revenue growth points and has successfully established partnerships with online e-commerce platforms[38]. - The company has established a comprehensive quality assurance system and a technology core system integrating independent intellectual property and innovative technology[33]. - The company has a mature marketing team and distribution network, which are crucial components of its core competitiveness[42]. - The company’s marketing strategy included a dual approach of "product + market," enhancing service and expanding its OTC market presence[49]. Research and Development - The company has several ongoing R&D projects aimed at expanding product categories and enhancing competitiveness through consistency evaluations[70][72]. - The company’s R&D expenses increased significantly, reflecting its commitment to product development despite the challenges posed by centralized procurement policies[46]. - Total R&D investment reached ¥42,677,839.70, a 54.00% increase compared to the previous year, representing 1.91% of operating revenue[73]. - The company emphasized talent cultivation, successfully recruiting over ten key talents to strengthen its R&D and quality capabilities[51]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements and future performance predictions[5]. - The company has outlined potential risks and countermeasures in its management discussion and analysis section[5]. - The company faces risks from industry policy changes, raw material price increases, and drug price reductions, and plans to respond by enhancing product quality and accelerating new product development[93][94]. - The company recognizes the need for continuous improvement in management and operational capabilities to adapt to industry changes[98]. Governance and Compliance - The company emphasizes strict compliance with information disclosure regulations, ensuring timely and accurate information is available to all shareholders[104]. - The company has established a fair and effective performance evaluation system for senior management, aligning annual business goals with clear responsibilities and quantifiable assessments[104]. - The company maintains complete independence from its controlling shareholders in business, personnel, assets, institutions, and finance, ensuring stable and independent operations[107]. - The company has an independent financial department with a standardized accounting system, reinforcing its autonomous operational capabilities[108]. - The governance structure of the company aligns with legal and regulatory requirements, with no significant discrepancies noted[106]. Employee and Organizational Structure - The total number of employees at the end of the reporting period was 783, with 545 in the parent company and 238 in major subsidiaries[132]. - The company has a comprehensive training program for employees, focusing on skills, professional knowledge, and practical knowledge[134]. - The employee composition includes 224 production personnel, 196 sales personnel, 104 technical personnel, 38 financial personnel, and 221 administrative personnel[132]. - The company has a salary policy that combines fixed salary, performance bonuses, excess profit bonuses, and other bonuses to motivate employees[133]. Legal and Regulatory Matters - The company did not encounter any risks during the supervisory activities of the supervisory board in the reporting period[131]. - The company has no penalties from securities regulatory authorities for current or recently departed directors, supervisors, and senior management[121]. - The company has reported a total of CNY 3.91 million in other litigation cases, which are still ongoing[180]. - The company has no significant leasing or contracting matters during the reporting period[196][197].

Financial Performance - Revenue for Q1 2022 was ¥482,036,482.63, a decrease of 5.91% compared to ¥512,301,458.44 in Q1 2021[3] - Net profit attributable to shareholders was ¥11,872,378.05, down 48.38% from ¥22,998,217.21 in the same period last year[3] - Basic earnings per share decreased by 48.45% to ¥0.0199 from ¥0.0386 in Q1 2021[3] - Total operating revenue for Q1 2022 was CNY 482,036,482.63, a decrease of 5.9% compared to CNY 512,301,458.44 in the previous year[20] - Net profit for Q1 2022 was CNY 11,871,474.86, a decline of 48.3% from CNY 22,997,368.17 in Q1 2021[21] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.0199, down from CNY 0.0386 in the previous year[22] Cash Flow and Assets - Net cash flow from operating activities improved by 74.63%, reaching -¥3,878,417.69 compared to -¥15,287,950.66 in Q1 2021[3] - Cash flow from operating activities for Q1 2022 showed a net outflow of CNY 3,878,417.69, an improvement from a net outflow of CNY 15,287,950.66 in Q1 2021[24] - Cash and cash equivalents at the end of Q1 2022 were CNY 343,435,836.55, down from CNY 351,310,626.07 at the end of Q1 2021[24] - The company's cash and cash equivalents were CNY 440,612,457.89, down from CNY 446,260,598.94 at the beginning of the year[16] - As of March 31, 2022, the total current assets amounted to CNY 2,151,498,007.79, a decrease from CNY 2,170,219,968.08 at the beginning of the year, representing a decline of approximately 0.86%[17] Expenses and Liabilities - Total operating costs for Q1 2022 were CNY 468,535,025.64, down 3.2% from CNY 484,059,251.82 in the same period last year[20] - R&D expenses increased by 70.67% to ¥2,236,380.58, reflecting higher investment in research and development[7] - Research and development expenses increased to CNY 2,236,380.58 in Q1 2022, compared to CNY 1,310,327.26 in the same period last year, reflecting a focus on innovation[20] - Sales expenses decreased significantly to CNY 135,390,427.74 in Q1 2022 from CNY 179,418,259.20 in Q1 2021, indicating cost control measures[20] - The total liabilities decreased to CNY 1,175,123,350.16 from CNY 1,206,677,909.88, indicating a reduction of about 2.6%[18] Shareholder Information - Shareholder equity attributable to shareholders increased by 0.89% to ¥1,352,023,044.58 from ¥1,340,151,569.72 at the end of the previous year[3] - The total equity attributable to shareholders of the parent company was CNY 1,352,023,044.58, an increase from CNY 1,340,151,569.72 year-over-year[21] - The number of ordinary shareholders at the end of the reporting period was 101,076[9] Tax and Subsidies - The company reported a significant reduction in income tax expenses, down 60.23% to ¥2,178,557.71 due to decreased profitability[7] - The company received government subsidies amounting to ¥181,377.81 during the reporting period[6] Regulatory and Legal Matters - The company received approval from the National Medical Products Administration for the chemical drug "Trimebutine Hydrochloride Sustained-Release Tablets" on January 11, 2022[11] - The company signed a supplementary agreement to mitigate guarantee risks with Southwest Synthetic Pharmaceutical Group, achieving substantial progress in risk resolution[12] - The company is in the process of resolving a construction contract dispute with Jiangsu Huajian Construction Co., achieving substantial progress in risk mitigation[14] Market Activity - The company disclosed a significant fluctuation in stock prices, with cumulative price deviation exceeding 20% over several trading days in March 2022[14] - The company is expected to engage in daily related transactions with China Ping An and its affiliates, as approved by the board of directors[11] Audit and Reporting - The first quarter report for 2022 has not been audited[25] - The report was released by the Board of Directors on April 29, 2022[26]

证券代码：000788 证券简称：北大医药 公告编号：2021-048 北大医药股份有限公司 关于参加"重庆辖区上市公司 2021 年投资者 网上集体接待日活动"的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为提高上市公司质量，推动重庆辖区上市公司进一步做好投资者关系管理工 作，在重庆证监局指导下，重庆上市公司协会联合上证所信息网络有限公司、深 圳市全景网络有限公司举办辖区上市公司 2021 年投资者网上集体接待日活动。 本次活动将于 2021 年 11 月 25 日（星期四）下午 15:00-17:00 举行，将通过深 圳市全景网络有限公司提供的网上平台，采取网络远程的方式进行，投资者可以 通过"全景·路演天下"（http://rs.p5w.net）进入专区页面参与交流。 届时，公司有关高级管理人员将参加本次活动，就公司治理、经营状况及投 资者所关心的问题，与投资者进行"一对多"形式的在线沟通和交流。欢迎广大 投资者积极参与。 特此公告。 北大医药股份有限公司 董 事 会 二〇二一年十一月二十日 ...

Financial Performance - The company's revenue for Q3 2021 reached ¥590,092,977.81, an increase of 4.48% year-over-year, while the year-to-date revenue was ¥1,693,912,427.73, up 21.67% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2021 was ¥22,593,175.48, representing a 41.05% increase year-over-year, and year-to-date net profit was ¥55,512,494.80, up 44.87%[3]. - The basic earnings per share for Q3 2021 was ¥0.0379, a 40.92% increase compared to the same period last year, with diluted earnings per share also at ¥0.0379[3]. - Total operating revenue for the third quarter of 2021 reached ¥1,693,912,427.73, an increase of 21.7% compared to ¥1,392,206,192.61 in the same period last year[22]. - The total profit for Q3 2021 was CNY 70,963,914.43, up from CNY 48,104,350.73 in Q3 2020, which is an increase of approximately 47.3%[23]. - Net profit for Q3 2021 reached CNY 55,518,176.84, compared to CNY 38,315,910.60 in Q3 2020, reflecting a growth of about 44.9%[23]. Assets and Liabilities - The company's total assets as of the end of Q3 2021 were ¥2,390,098,431.34, reflecting a 3.64% increase from the end of the previous year[3]. - The total liabilities as of September 30, 2021, were ¥1,043,107,302.87, compared to ¥1,014,727,869.44 at the end of 2020, representing an increase of 2.8%[20]. - The company's cash and cash equivalents decreased to ¥452,620,643.52 from ¥476,959,296.66, a decline of 5.1%[18]. - Accounts receivable increased to ¥1,254,180,192.37, up 7.8% from ¥1,163,039,543.29 at the end of 2020[18]. - The company's total equity attributable to shareholders increased by 4.28% to ¥1,352,520,226.16 compared to the end of the previous year[3]. - The total equity attributable to shareholders was approximately CNY 1.29 billion, with retained earnings of CNY 448.93 million[31]. Research and Development - Research and development expenses for the first nine months of 2021 amounted to ¥19,671,088.05, a significant increase of 211.41% year-over-year, primarily due to expenses related to the development of Ceftriaxone Sodium[6]. - The company reported a significant increase in intangible assets, which rose by 106.90% to ¥63,181,546.31, mainly due to the recognition of new products such as Celecoxib capsules[6]. - The company received approval for the drug registration certificate for Celecoxib capsules and the supplementary application approval for Cefminox sodium injection, indicating progress in new product development[16]. Cash Flow - The net cash flow from operating activities for the first nine months of 2021 was ¥24,600,318.25, a substantial increase of 291.42% compared to the same period last year[6]. - Cash flow from operating activities generated a net inflow of CNY 24,600,318.25, a turnaround from a net outflow of CNY 12,850,917.45 in the same period last year[27]. - The company incurred a net cash outflow from investing activities of CNY 24,111,859.37, compared to CNY 41,079,151.11 in the previous year, showing a decrease in outflow by approximately 41.2%[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,314[8]. - Southwest Synthetic Pharmaceutical Group Co., Ltd. holds 28.58% of shares, totaling 170,356,260 shares[8]. - Peking University Medical Industry Group Co., Ltd. holds 11.80% of shares, totaling 70,328,949 shares[8]. - The top ten shareholders include Chongqing Yangtze Pharmaceutical Factory with 1.21% (7,184,250 shares) and Beijing Zhengquan Holdings Co., Ltd. with 0.54% (3,225,346 shares)[8]. Corporate Governance - The company has completed the election of the 10th Board of Directors and Supervisory Board, with Song Jinsong elected as the chairman[11]. - The company has engaged a new board secretary, Yuan Yufei, as part of its management changes[12]. - The company has revised its Articles of Association as approved in the 2020 annual general meeting[12]. Restructuring - The company is in the process of restructuring, with a deadline for the restructuring plan extended to April 30, 2021[9]. - The restructuring investor consortium includes Zhuhai Huafa Group, China Ping An Insurance, and Shenzhen Special Zone Development Group[10]. - The company is in the process of restructuring its ownership, with Ping An Life becoming the controlling shareholder, holding 40.40% of the total shares[15].

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,103,819,449.92, representing a 33.41% increase compared to CNY 827,402,545.48 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 32,919,319.32, up 47.61% from CNY 22,300,878.94 year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 32,538,690.29, reflecting a 37.26% increase from CNY 23,706,187.12 in the previous year[20]. - The basic earnings per share increased to CNY 0.0552, a rise of 47.59% compared to CNY 0.0374 in the same period last year[20]. - The total profit for the first half of 2021 was CNY 44,596,340.06, an increase of 51.7% from CNY 29,373,598.83 in the first half of 2020[154]. - The company's total revenue for the reporting period reached ¥1,103,819,449.92, representing a year-on-year increase of 33.41% due to recovery in pharmaceutical distribution business after the pandemic[40]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,312,175,435.45, a slight increase of 0.26% from CNY 2,306,200,821.07 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company rose to CNY 1,329,927,050.68, marking a 2.54% increase from CNY 1,297,007,731.36 at the end of the previous year[20]. - Accounts receivable increased to ¥1,230,030,287.44, representing 53.20% of total assets, up from 50.43% the previous year[47]. - Cash and cash equivalents decreased to ¥411,774,988.33, making up 17.81% of total assets, down from 20.68%[47]. - Short-term borrowings decreased to ¥227,913,272.68, which is 9.86% of total assets, down from 11.07%[47]. - The total liabilities decreased to CNY 987,776,709.91 from CNY 1,014,727,869.44 at the end of 2020, indicating improved financial health[147]. Cash Flow - The net cash flow from operating activities was negative at CNY -30,376,374.32, a significant decline of 622.62% compared to CNY -4,203,664.40 in the same period last year[20]. - The company reported a cash inflow from operating activities of CNY 1,138,444,258.51, compared to CNY 901,052,088.98 in the same period of 2020, indicating strong cash generation[161]. - Total cash inflow from operating activities was 1,179,855,293.26 CNY, while cash outflow was 1,210,231,667.58 CNY, resulting in a net cash outflow of 30,376,374.32 CNY[162]. - The cash flow from investment activities showed a net outflow of 13,706,274.88 CNY, compared to a net outflow of 35,766,279.84 CNY in the previous year, reflecting a decrease in investment expenditures[163]. - Cash flow from financing activities resulted in a net outflow of 17,640,222.71 CNY, down from 41,423,318.47 CNY in the same period last year, indicating reduced financing costs[163]. Research and Development - The company focused on three major drug areas: anti-infection, mental health, and analgesics, and has made progress in the consistency evaluation of generic drugs[29]. - Research and development expenses rose by 18.99% to ¥13,887,117.94, reflecting the company's commitment to innovation[40]. - Research and development expenses increased significantly to CNY 18,438,632.04, compared to CNY 4,089,193.53 in the first half of 2020, reflecting a focus on innovation[152]. Market Strategy - The company has implemented a dual-channel marketing strategy, enhancing both online and offline sales efforts to improve market penetration[30]. - The company has established a strong marketing network covering the entire country, enhancing its competitive advantage in the market[37]. - The company plans to enhance market competitiveness by introducing new products and increasing marketing efforts for existing products[59]. Compliance and Governance - The company maintained compliance and risk management, ensuring effective communication with regulators and investors to support healthy market operations[31]. - The company has committed to avoiding any business that competes with its main operations, ensuring that no related parties engage in such activities, with a long-term commitment to this promise[76]. - The company has established a governance structure that allows its board and management to operate independently without undue influence from related parties[77]. - The company has committed to maintaining a healthy corporate governance structure, ensuring that all decisions are made in accordance with legal and regulatory frameworks[78]. Legal and Regulatory Matters - The company is currently involved in legal disputes that have resulted in frozen funds totaling approximately ¥47,500,000[51]. - The company has a pending arbitration case with Jiangsu New First Pharmaceutical Co., Ltd. involving a claim of 5,141.25 million yuan, which is currently unresolved[94]. - The company has been ordered to pay 14,969,161.59 yuan to Jiangsu Huajian Construction Co., Ltd. as part of a court ruling related to a construction contract dispute[94]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,389, with significant shareholders including Southwest Synthetic Pharmaceutical Group Co., Ltd. holding 28.58%[131]. - The company’s major shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., has 170,356,260 shares frozen[131]. - The company has not reported any significant changes in the integrity status of its controlling shareholders or actual controllers[96]. Financial Reporting - The semi-annual financial report has not been audited[83]. - The financial report for the first half of 2021 was not audited[142]. - The audit report indicated that the impact of the qualified opinion on the financial position and cash flow of North China Pharmaceutical for the fiscal year 2020 could not be specifically determined due to lack of evidence[88].

Financial Performance - The company's operating revenue for 2020 was ¥1,977,422,147.25, a decrease of 21.19% compared to ¥2,509,080,051.01 in 2019[16]. - The net profit attributable to shareholders for 2020 was ¥39,181,478.94, down 21.93% from ¥50,188,596.06 in 2019[16]. - The basic earnings per share for 2020 was ¥0.0657, a decrease of 21.97% from ¥0.0842 in 2019[16]. - The total operating revenue for the year was approximately CNY 1.977 billion, with a quarterly breakdown of CNY 362.81 million in Q1, CNY 464.59 million in Q2, CNY 564.80 million in Q3, and CNY 585.22 million in Q4[21]. - The net profit attributable to shareholders for the year was CNY 39.34 million, with quarterly figures of CNY 10.26 million in Q1, CNY 12.04 million in Q2, CNY 16.02 million in Q3, and a significant drop to CNY 0.86 million in Q4[21]. - The total operating revenue for 2020 was CNY 2,074,453,586.65, a decrease of 20.76% compared to the previous year[60]. - The company's pharmaceutical industrial revenue remained stable, with a net profit of 37.42 million yuan, an increase of 36.35% year-on-year, despite the overall decline in revenue due to the pandemic[46]. - The company's total revenue for 2020 was ¥1,977,422,147.25, representing a decrease of 21.19% compared to ¥2,509,080,051.01 in 2019[58]. Cash Flow and Assets - The net cash flow from operating activities was -¥68,141,309.55, a significant decline of 1,078.49% compared to -¥5,782,069.05 in 2019[16]. - The company's cash flow management remains stable, with no significant changes reported in cash flow operations[70]. - Operating cash inflow decreased by 20.07% to ¥2,117,954,874.59 in 2020 compared to ¥2,649,873,880.39 in 2019[71]. - The net increase in cash and cash equivalents was -¥200,987,162.82, representing a decrease of 279.27% compared to the previous year[71]. - Accounts receivable increased to ¥1,163,039,543.29, accounting for 50.43% of total assets, up from 44.65% in 2019[74]. - Cash and cash equivalents decreased to ¥476,959,296.66, representing 20.68% of total assets, down from 27.19% at the beginning of the year[74]. - The company reported total assets of approximately 971.79 million RMB and net assets of about 693.37 million RMB[85]. Strategic Focus and Market Position - The company has undergone significant changes in its business structure, focusing on drug formulation and distribution while divesting from raw material production[16]. - The pharmaceutical manufacturing industry remains a key focus, with ongoing research and development in various therapeutic areas including anti-infectives and oncology[26]. - The company aims to expand its market presence by enhancing its marketing channels and deepening its engagement in key product areas[27]. - The increase in disposable income and aging population in China is driving the demand for pharmaceuticals, providing a long-term growth opportunity for the industry[32]. - The company has a diverse product portfolio, including antibiotics and medications for mental health and diabetes management[28]. - The company is focusing on innovation and quality improvement in response to the supply-side reforms in the pharmaceutical industry[35]. - The company aims to improve its market presence by developing key products and exploring new marketing channels, including online sales[90]. Research and Development - The company is leveraging its academic resources from Peking University to enhance its R&D capabilities and product offerings[26]. - The company invested in the consistency evaluation project, leading to a 58.24% increase in development expenses compared to the previous period[38]. - Research and development expenses amounted to CNY 27,712,465.48, representing 1.40% of operating revenue, an increase of 0.17% from the previous year[69]. - The company plans to enhance its R&D capabilities by building a high-level team and focusing on market-driven projects[94]. - The company is focusing on the development of high-value-added products and has initiated projects for new drugs such as FZ016 and the introduction of various market-potential products[49]. Operational Efficiency and Cost Management - Management expenses decreased by 19.29% year-on-year, reflecting the company's efforts to enhance operational efficiency and cost control[52]. - The total operating cost decreased by 29.98% to CNY 1,076,963,856.12, with the pharmaceutical distribution sector's cost dropping by 31.79%[65]. - The company achieved a significant reduction in sales expenses by 4.31% to CNY 663,822,839.43[68]. - The gross profit margin for the pharmaceutical manufacturing sector was 86.60%, showing a slight increase of 0.23% year-on-year[60]. Risk Management and Compliance - The company has faced risks in its operations, which are discussed in detail in the report[5]. - The company emphasizes strict adherence to operational standards to manage production risks related to product quality and safety[95]. - The company will actively monitor policy changes and adjust strategies accordingly to navigate the evolving pharmaceutical landscape[96]. - The company faces risks from industry policy changes, including drug approval and pricing regulations, and will enhance product quality and accelerate new product development to adapt to these changes[92]. Corporate Governance and Shareholder Relations - The company did not distribute dividends in 2019 and 2020, despite having profits available for distribution, indicating a focus on reinvestment[101]. - The company is committed to avoiding competition with its controlling shareholders and ensuring fair market practices in related transactions[108]. - The company has established a complete and independent financial accounting system[110]. - The company is committed to enhancing investor relations through timely and accurate information disclosure[172]. Legal and Regulatory Matters - The company is involved in a lawsuit with Jiangsu Huajian Construction Co., Ltd., with a judgment requiring payment of approximately ¥14.97 million for project costs and ¥5.80 million for downtime losses[131]. - The company has a pending arbitration case with Hubei Zhengkong Pharmaceutical Co., Ltd. regarding a debt transfer contract dispute, with an amount involved of ¥5.14 million[129]. - The company reported a total of ¥1.12 billion in expected liabilities related to ongoing litigation[129]. - The audit report issued by Tianjian CPA for the financial statements of Beida Pharmaceutical Company for 2020 includes a qualified opinion due to the inability to obtain sufficient audit evidence regarding the restructuring plan of Founder Group, which may significantly impact the financial statements[114].

Financial Performance - The company's operating revenue for Q1 2021 was ¥512,301,458.44, representing a 41.20% increase compared to ¥362,812,695.12 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥22,998,217.21, a significant increase of 124.20% from ¥10,257,967.08 in the previous year[8]. - The net profit after deducting non-recurring gains and losses was ¥22,752,671.65, up 123.97% from ¥10,158,581.00 year-on-year[8]. - The basic earnings per share for Q1 2021 was ¥0.0386, which is a 124.42% increase compared to ¥0.0172 in the same period last year[8]. - The total profit for Q1 2021 was approximately ¥28.48 million, up 122.08% from ¥12.82 million in Q1 2020[15]. - The total comprehensive income for Q1 2021 was CNY 22,997,368.17, compared to CNY 10,370,528.91 in Q1 2020, indicating a significant increase[48]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,319,603,895.99, reflecting a 0.58% increase from ¥2,306,200,821.07 at the end of the previous year[8]. - The total liabilities as of Q1 2021 amounted to CNY 250,631,016.71, a decrease of 4.5% from CNY 262,866,367.89 in the previous year[47]. - Total assets increased to CNY 2,319,603,895.99 as of March 31, 2021, compared to CNY 2,306,200,821.07 at the end of 2020, reflecting a growth of approximately 0.58%[38]. - Total liabilities decreased to CNY 1,005,133,576.19 from CNY 1,014,727,869.44, reflecting a reduction of about 0.70%[40]. - Current assets totaled CNY 2,029,740,215.61, slightly up from CNY 2,020,161,337.01, indicating a marginal increase of about 0.09%[38]. Cash Flow - The net cash flow from operating activities for Q1 2021 was -¥15,287,950.66, which is an improvement of 45.25% compared to -¥27,921,120.06 in the same period last year[8]. - Operating cash inflow for the current period reached ¥559,487,360.65, an increase of 25.1% compared to ¥447,205,856.53 in the previous period[54]. - Cash outflow for purchasing goods and services was ¥304,272,675.04, up 36% from ¥223,936,958.77 in the previous period[54]. - Cash and cash equivalents at the end of the period totaled ¥351,310,626.07, down from ¥524,714,007.50 in the previous period[55]. - The cash flow from operating activities showed a net increase of ¥5,738,006.21, a significant recovery from -¥26,551,936.57 in the previous period[56]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,505[11]. - The largest shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., held 28.58% of the shares, amounting to 170,356,260 shares, with 9,500,000 shares frozen[11]. - The controlling shareholder, Chengsheng Group, holds 170,356,260 shares, accounting for 28.58% of the total share capital, with 86,000,000 shares (14.43%) used for margin financing with Zhongtai Securities[23]. - The second largest shareholder, Peking University Medical, holds 70,328,949 shares, representing 11.80% of the total share capital, with 70,000,000 shares (11.75%) used for margin financing with Huajin Securities[24]. Contracts and Agreements - The company has entered into a joint research agreement for the development of the innovative drug SKL-PSL, with shared responsibilities among partners including clinical trials and regulatory submissions[16]. - The company has signed a long-term service contract with Peking University International Hospital, with an estimated total contract value of ¥1 billion per year for three years[19]. - The company has established an industrial merger fund with a target capital contribution of between ¥500 million and ¥700 million, with the company planning to invest ¥3 million[18]. Other Financial Metrics - The weighted average return on equity for Q1 2021 was 1.76%, an increase of 0.94% from 0.82% in the previous year[8]. - Research and development expenses for Q1 2021 were CNY 1,310,327.26, down 28.8% from CNY 1,842,713.96 in Q1 2020[47]. - The company reported a financial expense of CNY 2,706,487.29, which includes interest expenses of CNY 4,320,493.09, a decrease from CNY 5,965,761.47 in the previous year[47]. - The company has not engaged in any securities or derivative investments during the reporting period[27][28]. - There are no overdue commitments from the actual controller, shareholders, or related parties during the reporting period[26].